دورية أكاديمية
Phase 2, randomized, double-blind, placebo-controlled multi-center trial of the clinical and biological effects of anti-CD14 treatment in hospitalized patients with COVID-19 pneumoniaResearch in context
| العنوان: | Phase 2, randomized, double-blind, placebo-controlled multi-center trial of the clinical and biological effects of anti-CD14 treatment in hospitalized patients with COVID-19 pneumoniaResearch in context |
|---|---|
| المؤلفون: | F. Linzee Mabrey, Hui Nian, Chang Yu, Elizabeth M. Barnes, Uma Malhotra, Carmen Mikacenic, Julia Goldstein, D. Shane O'Mahony, Julia Garcia-Diaz, Patricia Finn, Kirk Voelker, Eric D. Morrell, Wesley H. Self, Patrice M. Becker, Thomas R. Martin, Mark M. Wurfel |
| المصدر: | EBioMedicine, Vol 93, Iss , Pp 104667- (2023) |
| بيانات النشر: | Elsevier, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Medicine LCC:Medicine (General) |
| مصطلحات موضوعية: | COVID-19, CD14, CD14-blockade, Innate immunity, IC14, Medicine, Medicine (General), R5-920 |
| الوصف: | Summary: Background: Severe COVID-19 is associated with innate immunopathology, and CD14, a proximal activator of innate immunity, has been suggested as a potential therapeutic target. Methods: We conducted the COVID-19 anti-CD14 Treatment Trial (CaTT), a Phase II randomized, double-blind, placebo-controlled trial at 5 US-sites between April 12, 2021 and November 30, 2021 (NCT04391309). Hospitalized adults with COVID-19 requiring supplemental oxygen ( |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2352-3964 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S2352396423002323; https://doaj.org/toc/2352-3964 |
| DOI: | 10.1016/j.ebiom.2023.104667 |
| URL الوصول: | https://doaj.org/article/e8fbf755cfe945669342f97ba73dd512 |
| رقم الأكسشن: | edsdoj.8fbf755cfe945669342f97ba73dd512 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 23523964 |
|---|---|
| DOI: | 10.1016/j.ebiom.2023.104667 |